| SOXS 1.8134 1.31% | TPET 1.0099 140.45% | ONDS 10.685 6.00% | STAK 0.7273 71.13% | NVDA 182.49 2.99% | TMDE 2.38 158.08% | TURB 1.195 76.93% | BITO 9.53 5.19% | XLE 56.825 1.62% | RYDE 0.3346 44.60% | EONR 0.4951 14.61% | NOK 8.31 7.64% | TZA 6.1006 -2.08% | BHAT 0.039 -21.21% | NVD 7.0729 -6.07% | IBIT 39.235 5.50% | USEG 1.1477 7.26% | TQQQ 49.77 0.50% | PLUG 1.7892 -0.04% | MSTX 2.4874 10.55% | TSLS 5.645 0.09% | AES 14.3 -17.25% | JDST 1.23 6.03% | AAL 12.53 -4.13% | PLTR 146.02 6.44% | BATL 10.45 89.31% | NFLX 97.185 0.98% | HYG 80.345 -0.46% | SQQQ 70.49 -0.51% | TSLL 14.645 -0.37% | QQQ 608.4 0.18% | SOFI 18.145 2.17% | MARA 9.485 6.10% | ETHA 15.38 5.92% | XLF 51.425 -0.01% | INTC 45.0699 -1.18% | NU 15.195 1.44% | IWM 263.25 0.70% | TLT 89.495 -1.46% | TSLA 401.9 -0.15% | BMNR 20.52 8.11% | CRCG 2.9598 23.33% | NIO 4.72 -3.08% | VG 11.12 14.76% | BYND 0.8594 -9.12% | BANL 0.6087 34.82% | BKLN 20.245 0.17% | RCAT 13.7841 18.32% | LQD 110.885 -0.71% | KOS 2.195 -5.79%

LifeVantage Corporation (NASDAQ: LFVN) Q4 Earnings Overview

LifeVantage Corporation (NASDAQ: LFVN) is a health and wellness company known for its focus on nutritional supplements and skincare products. The company operates globally, with significant markets in the Americas, Asia/Pacific, and Europe. LifeVantage competes with other health and wellness companies, striving to maintain its market position through innovative products and strategic growth.

On September 4, 2025, LifeVantage reported its Q4 earnings, revealing an earnings per share (EPS) of $0.14, which fell short of the expected $0.17. Despite this, the company showed a year-over-year improvement, with net income per diluted share rising to $0.15 from $0.10. Adjusted earnings per diluted share also increased to $0.17 from $0.14, indicating some positive financial momentum.

The company's revenue for the fourth quarter was $55.1 million, below the anticipated $57.9 million. However, this still represented a 12.6% increase from the previous year. In the Americas, revenue grew by 14.1%, while Asia/Pacific and Europe saw a 7.6% increase. Excluding foreign currency impacts, the growth in Asia/Pacific and Europe was 1.6%, highlighting regional performance variations.

LifeVantage's financial metrics provide further insight into its market position. The company has a price-to-earnings (P/E) ratio of 15.22 and a price-to-sales ratio of 0.67, indicating how the market values its earnings and revenue. The enterprise value to sales ratio is 0.62, suggesting a slightly lower valuation when accounting for debt and cash.

The company's financial health is supported by a debt-to-equity ratio of 0.36, reflecting moderate debt levels. With a current ratio of 1.66, LifeVantage demonstrates strong liquidity, ensuring it can meet short-term liabilities. The earnings yield of 6.57% offers insight into the earnings generated per dollar invested, showcasing the company's profitability.

Published on: September 5, 2025